Seelos Therapeutics, Inc. NXEN.F Stock
Seelos Therapeutics, Inc. Price Chart
Seelos Therapeutics, Inc. NXEN.F Financial and Trading Overview
Seelos Therapeutics, Inc. stock price | 0.11 EUR |
Previous Close | 1.01 EUR |
Open | 0.95 EUR |
Bid | 0.95 EUR x 0 |
Ask | 0.97 EUR x 0 |
Day's Range | 0.95 - 0.95 EUR |
52 Week Range | 0.55 - 1.39 EUR |
Volume | 5K EUR |
Avg. Volume | 194 EUR |
Market Cap | 115.6M EUR |
Beta (5Y Monthly) | 1.930755 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.5 EUR |
NXEN.F Valuation Measures
Enterprise Value | 129.89M EUR |
Trailing P/E | N/A |
Forward P/E | -2.1088889 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 143.06763 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 160.756 |
Enterprise Value/EBITDA | N/A |
Trading Information
Seelos Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 1.930755 |
52-Week Change | 72.87% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.39 EUR |
52 Week Low | 0.55 EUR |
50-Day Moving Average | 0.75 EUR |
200-Day Moving Average | 0.83 EUR |
NXEN.F Share Statistics
Avg. Volume (3 month) | 194 EUR |
Avg. Daily Volume (10-Days) | 768 EUR |
Shares Outstanding | 121.81M |
Float | 118.38M |
Short Ratio | N/A |
% Held by Insiders | 2.81% |
% Held by Institutions | 19.89% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -8148.26% |
Gross Margin | 637.25% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -87.23% |
Return on Equity (ttm) | -584.20% |
Income Statement
Revenue (ttm) | 808K EUR |
Revenue Per Share (ttm) | 0.007 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | N/A |
Net Income Avi to Common (ttm) | -72964000 EUR |
Diluted EPS (ttm) | -0.78 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 14.06M EUR |
Total Cash Per Share (mrq) | 0.12 EUR |
Total Debt (mrq) | 16.78M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.602 |
Book Value Per Share (mrq) | -0.17 |
Cash Flow Statement
Operating Cash Flow (ttm) | -54907000 EUR |
Levered Free Cash Flow (ttm) | -16162500 EUR |
Profile of Seelos Therapeutics, Inc.
Country | Germany |
State | NY |
City | New York |
Address | 300 Park Avenue |
ZIP | 10022 |
Phone | 646 293 2100 |
Website | https://seelostherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 16 |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
Q&A For Seelos Therapeutics, Inc. Stock
What is a current NXEN.F stock price?
Seelos Therapeutics, Inc. NXEN.F stock price today per share is 0.11 EUR.
How to purchase Seelos Therapeutics, Inc. stock?
You can buy NXEN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Seelos Therapeutics, Inc.?
The stock symbol or ticker of Seelos Therapeutics, Inc. is NXEN.F.
Which industry does the Seelos Therapeutics, Inc. company belong to?
The Seelos Therapeutics, Inc. industry is Biotechnology.
How many shares does Seelos Therapeutics, Inc. have in circulation?
The max supply of Seelos Therapeutics, Inc. shares is 161.38M.
What is Seelos Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Seelos Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was Seelos Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Seelos Therapeutics, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Seelos Therapeutics, Inc. company belong to?
The Seelos Therapeutics, Inc. sector is Healthcare.